Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Terbutaline
Teriflunomide	TA303 - Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide injection	TA161 - Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Terlipressin injection		Hospital use only
Testosterone implant		Hospital only - menopausal clinic
Tetanus immunoglobulin 250units injection
Tetracaine hydrochloride Minims® amethocaine hydrochloride		For hospital use only
Tetracosactide injection
Tezacaftor and ivacaftor (Symkevi®)		NHSE commissioning statement
Thalidomide

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.